Combat Methamphetamine Epidemic Act 2005 (CMEA)

Final Rule: Implementation of the Combat Methamphetamine Epidemic Act of 2005; Retail Sales; Notice of Transfers Following Importation or Exportation (October 29, 2020)

Drug Scheduling Actions

Order With Opportunity for Comment: Exempt Anabolic Steroid Products (December 16, 2020)

Notice of Intent: Temporary Placement of Brorphine in Schedule I (December 3, 2020)

Final Rule: Placement of cyclopentyl fentanyl, isobutyryl fentanyl, para-chloroisobutyryl fentanyl, para-methoxybutyryl fentanyl, and valeryl fentanyl in Schedule I (November 25, 2020)

Interim Final Rule: Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment (PDF) (November 2, 2020)

Interim Final Rule: Placement of Oliceridine in Schedule II (October 30, 2020)

Interim Final Rule: Placement of Remimazolam in Schedule IV (October 6, 2020)

Final Order: Placement of Crotonyl Fentanyl in Schedule I (October 2, 2020)

Temporary Rule: Extension of Temporary Placement of N-Ethylpentylone in Schedule I of the Controlled Substances Act (August 27, 2020)

Interim Final Rule: Implementation of the Agriculture Improvement Act of 2018 (August 21, 2020)

Final Rule: Placement of Cenobamate in Schedule V (August 20, 2020)

Temporary Order: Temporary Placement of Isotonitazene in Schedule I (August 20, 2020)

Extension of Temporary Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA in Schedule I of the Controlled Substances Act (July 13, 2020)

Final Rule: Listing of Ethylone in Schedule I of Controlled Substances (June 8, 2020)

Final Rule: Control of the Immediate Precursor Norfentanyl Used in the Illicit Manufacture of Fentanyl as a Schedule II Controlled Substance (April 17, 2020)

Final Rule: Designation of Benzylfentanyl and 4-Anilinopiperidine, Precursor Chemicals Used in the Illicit Manufacture of Fentanyl, as List I Chemicals (April 15, 2020)

Temporary Placement of Fentanyl-Related Substances in Schedule I; Correction (April 10, 2020)

Interim Final Rule: Placement of Lemborexant in Schedule IV (April 7, 2020)

Final Rule: Placement of FUB-AMB in Schedule I (March 30, 2020)

Interim Final Rule: Placement of Cenobamate in Schedule V (March 10, 2020)

Interim Final Rule: Placement of Lasmiditan in Schedule V (January 31, 2020)

Temporary Rule: Extension of Temporary Placement of cyclopentyl fentanyl, isobutyryl fentanyl, para-chloroisobutyryl fentanyl, para-methoxybutyryl fentanyl, and valeryl fentanyl in Schedule I (January 30, 2020)

Direct Final Rule: Additions to Listing of Exempt Chemical Mixtures (January 27, 2020)

Final Rule: Placement of 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA in Schedule I (January 24, 2020)

Final Rule: Removal of 6β-Naltrexol From Control (January 24, 2020)

Final Rule: Placement of Brexanolone in Schedule IV (January 24, 2020)

Final Rule: Placement of Solriamfetol in Schedule IV (January 7, 2020)

Electronic Prescriptions for Controlled Substances

Interim Final Rule; Reopening of Comment Period; Electronic Prescriptions for Controlled Substances (April 21, 2020)

Exempt Anabolic Steroid Products

Order with Opportunity for Comment: Exempt Anabolic Steroid Products (June 15, 2020)

Marijuana

Final Rule: Controls To Enhance the Cultivation of Marihuana for Research in the United States (PDF) (December 18, 2020)

Proposed Rules

Proposed Rule: Designation of 3,4-MDP-2-P Methyl Glycidate (PMK Glycidate), 3,4-MDP-2-P Methyl Glycidic Acid (PMK Glycidic Acid), and Alpha-Phenylacetoacetamide (APAA) as List I Chemicals (December 21, 2020)

Proposed Rule: Removal of Samidorphan From Control (December 10, 2020)

Proposed Rule: Partial Filling of Prescriptions for Schedule II Controlled Substances (PDF) (December 4, 2020)

Proposed Rule: Suspicious Orders of Controlled Substances (PDF) (November 2, 2020)

Proposed Rule: Registering Emergency Medical Services Agencies Under the Protecting Patient Access to Emergency Medications Act of 2017 (PDF) (October 5, 2020)

Proposed Rule: Default Provisions for Hearing Proceedings Relating to the Revocation, Suspension, or Denial of a DEA Registration (September 30, 2020)

Proposed Rule: Placement of N-Ethylpentylone in Schedule I (August 27, 2020)

Proposed Rule: Reporting of Theft or Significant Loss of Controlled Substances (July 29, 2020)

Proposed Rule: Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA in Schedule I (July 13, 2020)

Proposed Rule: Temporary Placement of Isotonitazene in Schedule I (June 18, 2020)

Proposed Rule: Placement of para-Methoxymethamphetamine (PMMA) in Schedule I (May 15, 2020)

Proposed Rule: Placement of Zipeprol in Schedule I (May 14, 2020)

Proposed Rule: Placement of 4,4'-DMAR in Schedule I (April 7, 2020)

Proposed Rule: Controls To Enhance the Cultivation of Marihuana for Research in the United States (PDF) (March 23, 2020)

Proposed Rule: Registration and Reregistration Fees for Controlled Substance and List I Chemical Registrants (PDF) (March 16, 2020)

Proposed Rule: Registration Requirements for Narcotic Treatment Programs with Mobile Components (February 26, 2020)

Proposed Rule: Placement of cyclopentyl fentanyl, isobutyryl fentanyl, para-chloroisobutyryl fentanyl, para-methoxybutyryl fentanyl, and valeryl fentanyl Into Schedule I (January 30, 2020)

Registration

Final Rule: Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008; Correction (October 22, 2020)

Final Rule: Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (September 30, 2020)

Final Rule: Registration and Reregistration Fees for Controlled Substance and List I Chemical Registrants (PDF) (July 24, 2020)

NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Publishing Office (GPO).